Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MME | P08473 | 5/20 | 0.44 |
| ▸ | FOLH1 | Q04609 | 1/20 | 0.40 |
| ▸ | OPRM1 | P35372 | 3/20 | 0.39 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.39 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.39 |
| ▸ | LTA4H | P09960 | 1/20 | 0.38 |
| ▸ | ACE | P12821 | 1/20 | 0.38 |
| ▸ | TAS1R3 | Q7RTX0 | 1/20 | 0.37 |
| ▸ | TAS1R1 | Q7RTX1 | 1/20 | 0.37 |
| ▸ | CTSS | P25774 | 1/20 | 0.37 |
| ▸ | CTSK | P43235 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5870042 | 1.00 | MME (0.44) | MMEFOLH1OPRM1OPRD1OPRK1 | |
| SCHEMBL8248805 | 0.81 | FOLH1 (0.48) | MMEFOLH1LTA4HACE | |
| SCHEMBL5869820 | 0.81 | FOLH1 (0.48) | MMEFOLH1LTA4HACE | |
| SCHEMBL5869880 | 0.78 | CYP2C19 (0.49) | CTSK | |
| SCHEMBL8258150 | 0.78 | CYP2C19 (0.49) | CTSK | |
| SCHEMBL22092489 | 0.76 | MME (0.43) | MMEOPRM1OPRD1OPRK1CTSS | |
| SCHEMBL2628231 | 0.74 | MME (0.45) | MMEOPRM1OPRD1OPRK1CTSS | |
| SCHEMBL754158 | 0.74 | MME (0.45) | MMEOPRM1OPRD1OPRK1CTSS | |
| SCHEMBL5869885 | 0.73 | MMP3 (0.47) | MMELTA4HACE | |
| SCHEMBL8255233 | 0.73 | MMP3 (0.47) | MMELTA4HACE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040082496-A1 | ACE-2 modulating compounds and methods of use thereof | MILLENNIUM PHARMACEUTICALS, INC. | 2004-04-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040082496-A1 | ACE-2 modulating compounds and methods of use thereof | ACE, ACE2, AGTR2 | MME 11/4885FOLH1 229/4885OPRM1 486/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.